Cholesterol

Article discusses Bayesian unmeasured confounding model for handling missing data in cholesterol levels, using unmconf in R to estimate unmeasured confounders and adjust for bias. It covers methodologies for addressing unmeasured confounders, Bayesian model formulation, prior distributions, and posterior inference.

GLP-1RAs like Ozempic and Wegovy, effective for diabetes and weight loss, face overuse concerns due to off-label popularity. Experts highlight their efficacy but warn of side effects, costs, and the need for personalized treatment. Research suggests combining GLP-1RAs with cheaper alternatives for weight maintenance could improve access and affordability.

Novo Nordisk increases Wegovy's starter dose supply to meet soaring demand, aiding more Americans in starting the weight-loss treatment. Wegovy, a GLP-1 receptor agonist, mimics a natural hormone to regulate appetite, approved for obesity and overweight with complications. Long-term use raises safety concerns, with side effects like nausea and potential for weight regain post-treatment. Doctors debate its long-term safety, emphasizing lifestyle changes alongside medication. Wegovy's effectiveness and side effects in teens and adults are under scrutiny, with calls for more long-term data.

Dr. Ernst von Schwarz predicts living to 120 will be attainable this decade, with 150 becoming normal by century's end, thanks to stem cell advances. Achieving this requires healthy living starting by age 30. Stem cells, not yet FDA-approved, promise to repair damage and extend healthy life, beyond superficial uses, despite ethical and sourcing challenges.

Metformin, a diabetes drug, shows promise in preventing aging-related diseases. Nir Barzilai's TAME Trial aims to prove this, facing FDA and funding hurdles. Despite interest, securing the $30-50M needed remains challenging, with hopes pinned on new philanthropists and organizations like Hevolution.